Table 1.
Variables used in multiple regression analyses and correlations with the outcome measures (N = 169)
| Variables | Description | Descriptives M & SD/Med & R /count (%) |
r Attention/Executive | r Verbal Memory | r CFS | |
|---|---|---|---|---|---|---|
| Outcome variables | ||||||
| Attention and executive factora | Objective attention/executive score (from PCA) | M: 0.0 | SD: 1.0 | 1 | 0.24d | 0.24d |
| Verbal memory factora | Objective verbal memory score (from PCA) | M: 0.0 | SD: 1.0 | 0.24d | 1 | 0.04 |
| CFS total scorea,c | Frequency of cognitive complaints (6–36) | M: 22.1 | SD: 4.4 | 0.24d | 0.04 | 1 |
| Predictor variables | ||||||
| Sociodemographic | ||||||
| Sex | Male vs female | 92 (54%) | 77 (46%) | 0.02 | 0.32d | −0.27d |
| Age | Years (range 20.8–69.7) | M: 43.2 | SD: 9.6 | −0.27d | −0.15e | −0.07 |
| Education | Low/middle vs high | 88 (52%) | 81 (48%) | 0.18e | 0.31d | 0.04 |
| Clinical | ||||||
| Hemisphere of lesion | Left vs right | 93 (55%) | 76 (45%) | 0.26d | 0.09 | −0.01 |
| Use of antiepileptic drugs in last year | No vs yes | 32 (19%) | 137 (81%) | −0.13 | 0.04 | −0.04 |
| History of radiotherapy | No vs yes | 62 (37%) | 107 (63%) | −0.03 | 0.07 | −0.06 |
| History of chemotherapy | No vs yes | 153 (91%) | 16 (9%) | −0.22d | −0.11 | −0.04 |
| Disease duration | Years | Med: 4.7 | R: 0.6–28.9 | −0.16e | −0.01 | −0.03 |
| Physical health symptoms | ||||||
| SF-36 physical component summary scorea | Physical-health-related quality of life21,22 (0–100) | M: 46.5 | SD: 9.2 | −0.03 | −0.02 | 0.25d |
| QLQ BN-20 visual disorderb | Visual disorder26 (3–12) | Med: 4.0 | R: 3.0–12.0 | −0.09 | −0.07 | −0.35d |
| QLQ BN-20 motor dysfunctionb | Motor dysfunction26 (3–12) | Med: 4.0 | R: 3.0–9.0 | −0.13 | −0.10 | −0.36d |
| Mental health symptoms | ||||||
| SF-36 mental component summary scorea | Mental-health-related quality of life21,22 (0–100) | M: 43.7 | SD: 10.1 | 0.12 | 0.02 | 0.33d |
| MFI mental fatigueb | Mental aspects of fatigue25 (4–20) | M: 14.3 | SD: 3.6 | −0.10 | −0.05 | −0.42d |
| QLQ BN-20 communication deficitb | Communication deficit26 (3–12) | M: 5.8 | SD: 2.0 | −0.32d | −0.15 | −0.39d |
| QLQ BN-20 future uncertaintyb | Future uncertainty26 (4–16) | M: 8.1 | SD: 2.9 | −0.07 | 0.00 | −0.20d |
Abbreviations: CFS, Cognitive Function Scale; M, mean; Med, median; MFI, Multidimensional Fatigue Inventory; PCA, principal component analysis; QLQ BN-20, Brain cancer specific Quality of Life Questionnaire; r, Pearson's product-moment correlation; R, range; SD, standard deviation; SF-36, Medical Outcomes Study Short-Form 36.
aHigher score indicates better (subjective/objective) functioning.
bHigher score indicates lower (subjective/ objective) functioning.
cfrom the MOS.20
dCorrelation is significant at the 0.01 level (2-tailed).
eCorrelation is significant at the 0.05 level (2-tailed).